Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.88 – $2.32
42% from low
Exchange
OTC Link
ADRC
Borrow rate
0.32%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.71B | $1.79B | $1.88B | $2.15B | $3.29B | $4.35B | $4.38B | $4.08B |
| Cost of revenue | $481.0M | $492.0M | $591.0M | $688.0M | $1.50B | $1.96B | $2.01B | $1.68B |
| Gross profit | $1.23B | $1.30B | $1.28B | $1.46B | $1.79B | $2.39B | $2.37B | $2.40B |
| Gross margin | 71.9% | 72.5% | 68.5% | 68.0% | 54.5% | 55.0% | 54.1% | 58.9% |
| R&D | $998.0M | $812.0M | $689.0M | $713.0M | $735.0M | $877.0M | $1.06B | $1.06B |
| Operating income | −$830.0M | −$1.04B | −$700.0M | −$1.04B | −$1.15B | −$2.02B | −$926.0M | −$1.17B |
| EBITDA | −$118.0M | $683.0M | −$278.0M | −$482.0M | −$616.0M | $18.0M | $16.0M | −$518.5M |
| Net income | −$632.0M | −$152.0M | −$59.0M | −$492.0M | −$298.0M | −$1.48B | −$577.0M | $162.2M |
| Net margin | -37.0% | -8.5% | -3.1% | -22.9% | -9.1% | -33.9% | -13.2% | 4.0% |
| EPS (diluted) | -2.94 | -0.71 | -0.27 | -2.29 | -1.39 | -6.99 | -2.73 | 0.77 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $4.7B | $0.00 | $0.00–$0.00 | 0 |
| 2028 | $5.6B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
CYBERDYNE INC SPNS/ADR
No one on the platform currently holds CYBQY.
No tracked institution reports a position in CYBQY as of their last filing.
No one on the platform has traded CYBQY yet.
| $539M |
| — |
| JWCTFJW (Cayman) Therapeutics Co. Ltd | $0.24 | +0.00% | $99M | — |
| MFCSFMedical Facilities Corporation | $12.76 | +0.47% | $224M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.1× historical median P/S.
Fair value ≈ $2.20 · price $1.49 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.